About Aduro BioTech (NASDAQ:ADRO)

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.

Receive ADRO News and Ratings via Email

Sign-up to receive the latest news and ratings for ADRO and its competitors with MarketBeat's FREE daily newsletter.

Profitability

Miscellaneous

Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions

What is Aduro BioTech's stock symbol?

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

How were Aduro BioTech's earnings last quarter?

Aduro BioTech Inc (NASDAQ:ADRO) posted its quarterly earnings results on Tuesday, October, 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.03. The biotechnology company earned $3.79 million during the quarter, compared to the consensus estimate of $4.04 million. Aduro BioTech had a negative return on equity of 37.86% and a negative net margin of 532.88%. The company's quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.54) earnings per share. View Aduro BioTech's Earnings History.

Where is Aduro BioTech's stock going? Where will Aduro BioTech's stock price be in 2018?

8 equities research analysts have issued twelve-month price objectives for Aduro BioTech's shares. Their forecasts range from $8.00 to $30.00. On average, they anticipate Aduro BioTech's share price to reach $15.67 in the next twelve months. View Analyst Ratings for Aduro BioTech.

What are Wall Street analysts saying about Aduro BioTech stock?

Here are some recent quotes from research analysts about Aduro BioTech stock:

1. According to Zacks Investment Research, "Aduro reported narrower-than-expected loss in the fourth quarter of 2017 while revenues missed estimates. The company has a broad, promising pipeline of novel immunotherapies under development for treatment of a variety of cancers. The company’s collaboration agreements with large pharma companies — Novartis and Johnson & Johnson — not only validate the company’s research platforms but also enhance its financial position, providing it with adequate funds. However, with no approved products in Aduro’s portfolio, the company heavily depends on funds generated from collaboration and license agreements, government grants as well as other payments for the development of its pipeline candidates. Thus, an inability to secure sufficient funding could hinder Aduro’s pipeline progress. Shares of the company have underperformed the industry in a year’s time." (3/7/2018)

2. Cantor Fitzgerald analysts commented, "ADRO shares are trading up modestly on the disclosure of a $3 million milestone from MRK’s (Merck, NC) initiation of a Phase I trial with the anti- CD27 candidate." (3/5/2018)

3. HC Wainwright analysts commented, "All Three Platforms Now Clinical Stage; We Have High Expectations for B-Select Platform B-select investment starts bearing clinical stage candidates. Aduro announced the expected initiation of a Phase 1/2 clinical trial with its anti-APRIL antibody, BION-1301. This two part, open-label study, is being conducted in relapsed or refractory multiple myeloma patients (at least three prior systemic therapies). Once the recommended Phase 2 dose is identified in part 1, patients are to be expanded at the selected dose with the primary endpoint of overall response rate. The APRIL/BCMA pathway was also a hot topic at the recent ASH conference as an encouraging new target against myeloma. A proliferation inducing ligand (APRIL) is one of the main high affinity ligands that binds and activates BCMA resulting in a pro-survival cell signal. APRIL is a member of the TNF family and is overexpressed in patients with multiple myeloma (MM)." (12/13/2017)

4. Canaccord Genuity analysts commented, "1Q17 results recap. Adjusted non-GAAP revenue (excluding the individual commercial business) grew 4.4% year over year. Adjusted MLR was 85.2% compared to 85.0% a year ago. MLR benefitted from the exit of certain Medicare markets, which was offset to some degree by lower prior period development when compared to a year ago. Cost trends appear to be in check, consistent with other publicly-traded health insurers." (5/3/2017)

Dirk G. Brockstedt, Executive Vice President of Research and Development (Age 48)

Andrea van Elsas Ph.D., Chief Scientific Officer

Natalie R. Sacks, Chief Medical Officer (Age 52)

Stephanie Monaghan O'Brien J.D., Lead Independent Director (Age 58)

Gerald Chan Ph.D., Independent Director (Age 66)

William M. Greenman, Independent Director (Age 50)

Ross Haghighat, Independent Director (Age 53)

When did Aduro BioTech IPO?

(ADRO) raised $119 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Has Aduro BioTech been receiving favorable news coverage?

Headlines about ADRO stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aduro BioTech earned a daily sentiment score of 0.12 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 49.22 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Aduro BioTech?

Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aduro BioTech's stock price today?

One share of ADRO stock can currently be purchased for approximately $9.50.

How big of a company is Aduro BioTech?

Aduro BioTech has a market capitalization of $745.26 million and generates $17.24 million in revenue each year. The biotechnology company earns $-91,860,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Aduro BioTech employs 162 workers across the globe.

MarketBeat Community Rating for Aduro BioTech (ADRO)

MarketBeat's community ratings are surveys of what our community members think about Aduro BioTech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Aduro BioTech (NASDAQ:ADRO) Analysts' Consensus Rating

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.